Login to Your Account



Sarepta's MAP to Exondys 51 sales: Joint effort cuts DMD pain

By Randy Osborne
Staff Writer

Wednesday, July 19, 2017

As investors waited Wednesday afternoon for Sarepta Therapeutics Inc.'s second-quarter earnings, news of a MAP with Clinigen Group plc's Idis division for Exondys 51 in DMD had Wall Street speculating that the deal would add to fiscal-year 2017 guidance of more than $95 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription